Logo Image

Belen San Antonio

Articles by Belen San Antonio

95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status

ByJavier Cortés, MD,Stephen R.D. Johnston,Miguel Martin, MD, PhD,Sara M. Tolaney, MD, MPH,Matthew P. Goetz, MD,Hope S. Rugo, MD,Joohyuk Sohn,Ozgur Ozyilkan,Miguel Henriques Abreu,Matthias Zaiss,Karina Maia Vianna,Hanne Melgaard Nielsen,Arlene Chan,Haralambos Kalofonos, MD,Serafin Morales,Belen San Antonio,Maria Munoz Fernandez,Sasha Amdur,Patrick Neven, MD, PhD,Brenda Grimes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

ByHope S. Rugo, MD,Nadia Harbeck, MD, PhD,Priya Rastogi, MD,Joyce O’Shaughnessy, MD,Frances Boyle,Javier Cortés, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Chiun-Sheng Huang,Elżbieta Senkus,Alexey Tryakin,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Valérie André,Maria Munoz,Belen San Antonio,Ashwin Shahir,Miguel Martin, MD, PhD,Stephen Johnston

Latest Updated Articles